Lupkynis (Voclosporin) Patent Expiration, LOE Window & CMS Spending

Lupkynis (Voclosporin) by Aurinia: FDA Orange Book core substance LOE 2027-10-17 (last listed 2037-12-07), 0 AB generics, $83.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAurinia
FDA Application & PathwayN213716 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2027-10-17
Last Listed Patent or Exclusivity Date2037-12-07
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$83.3M
2024 Medicare Part D Spend$25.8M
2024 Medicaid Spend$57.5M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 24.6% 2-yr change)